某三甲医院依达拉奉注射液用药合理性调查  

Investigation of Clinical Use Rationality of Edaravone Injection in a Class Three Grade A Hospital

作　　者：卢立山[1] 苏伊新[1] 郝海玲[1] 

机构地区：[1]鄂尔多斯市中心医院药剂科,内蒙古鄂尔多斯017010

出　　处：《中国药师》2017年第4期702-704,共3页China Pharmacist

摘　　要：目的:评价某院依达拉奉注射液临床应用合理性,提升临床合理用药水平。方法:利用该院病案管理系统,随机提取2016年1~6月应用依达拉奉注射液病历500份,依据药品说明书、相关文献与资料分析其临床应用合理性。结果:500份病历中神经外科占48%,神经内科37%,重症医学科7%,骨科5%,其他科室占3%。用药不合理病历共计261份(52.2%);其中超说明书适应证用药108份(21.6%);给药频次不当180份(36%);给药疗程不当201份(40.2%);给药时机不正确37份(7.4%);溶媒选择错误3份(0.6%);存在特殊人群使用4份(0.8%)。结论:依达拉奉注射液在该院存在严重的超疗程、超适应症使用等现象,且不能够严格遵照药品说明书规定的给药频次和注意事项合理用药,应引起高度重视。Objective： To evaluate the clinical use rationality of edaravone injection in our hospital to improve the level of rational use of drugs in clinics. Methods： Totally 500 medical records with edaravone injection from January to June in 2016 were selected randomly based on the hospital medical record management system. According to the drug package insert, relative literatures and information, the clinical use rationality was evaluated. Results： Among the 500 medical records, ncurosurgery patients accounted for 48%, nerve internal medicine patients accounted for 37%, ICU patients accounted for 7%, orthopedics patients accounted for 5%, and the patients in the other departments accounted for 3%. Among the 500 medical records, 108 ones involved off-label drug use, which accounted for 21.6%, 180 cases involved improper use frequency, which accounted for 36%, 201 cases involved improper treatment course, which accounted for 40.2% , 37 cases involved improper drug administration time, which accounted for 7.4%, 3 eases involved inappropriate solvent choice, which accounted for 0.6% , and 4 cases involved special population, which accounted for 0.8%. Among the 500 medical records, totally 261 （52.2%） ones were irrational. Conclusion ： The overdose use and improper treatment course of edaravone injection in our hospital are severe, meanwhile, improper frequency and notice ignorance are common as well, which should be paid more attention.

关 键 词：依达拉奉 脑梗死 合理应用 

分 类 号：R969.3[医药卫生—药理学]